Astellas Pharma
Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says
April 13, 2026Astellas Pharma, menopause
Final draft NICE guidance has recommended Veoza (fezolinetant), made by Astellas Pharma, to treat moderate to severe menopausal hot flushes …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
February 4, 2026Research and Development Astellas Pharma, Scottish Medicines Consortium, Vyloy, gastric cancer, oncology
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that Vyloy (zolbetuximab), in combination with …
The Pharma Files: With Colin Williams from Astellas Pharma
October 5, 2025Medical Communications, Research and Development Astellas Pharma, Corporate, The Pharma Files, pm society
Pharmafile chats with Colin Williams, Head of Marketing Excellence, Global Capabilities, Learning & Development at Astellas Pharma about the best …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
Astellas Pharma to acquire Propella Therapeutics for $175m
November 20, 2023Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition
Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …
Astellas plans to invest over €330m in new facility in Ireland
September 18, 2023Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing
Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at …
Astellas set to open new life sciences facilities in Cambridge, Massachusetts
August 10, 2023Business Development Astellas Pharma, Pharmacy, pharmaceutical, science facility
On 9 August 2023, Astellas Pharma announced its plans to open what it has described as a “state-of-the-art life sciences …
Astellas announces FDA approval for Izervay for GA treatment
August 7, 2023Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy
Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets
July 11, 2023Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology
Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …
FDA grants Priority Review for Astellas Pharma’s BLA for cancer drug
July 6, 2023Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology
Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …
Astellas establishes open innovation hub for tumour microenvironment research
June 29, 2023Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment
Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …
Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms
June 28, 2023Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause
Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …
Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib
June 9, 2023Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical
Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …
Astellas and Sony enter collaborative research agreement
May 16, 2023Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement
Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …
FDA approve Astellas’s Myrbetriq treatment for bladder dysfunction
March 26, 2021Medical Communications Astellas Pharma, FDA, Ida approval
The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), …
